^
Association details:
| Biomarker: | KMT2A rearrangement |
|---|---|
| Cancer: | Acute Lymphocytic Leukemia |
| Drug: | lestaurtinib (CEP-701) (JAK2 inhibitor, FLT3 inhibitor, STAT5 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children’s Oncology Group trial AALL0631
Published date:
02/23/2021
Excerpt:
After chemotherapy induction, KMT2A-r infants received either chemotherapy only or chemotherapy plus lestaurtinib....Seventeen patients were both inhibited and sensitive, with an EFS of 88 ± 8%....Patient selection and PD-guided dose escalation may enhance the efficacy of FLT3 inhibition for KMT2A-r infant ALL.
DOI:
10.1038/s41375-021-01177-6
Trial ID:
